Pyrazoles

Dec 03, 2018

Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib

Aug 22, 2018

Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences

Jul 02, 2018

CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib

Jun 13, 2018

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

Jun 03, 2018

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

Mar 29, 2018

Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023

Aug 01, 2017

CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib

Jun 05, 2017

Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health